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A B S T R A C T
DNA vaccination is an attractive technology, based on its well-established manufacturing process, safety profile,
adaptability to rapidly combat pandemic pathogens, and stability at ambient temperature; however an optimal
delivery method of DNA remains to be determined. As pigs are a relevant model for humans, we comparatively
evaluated the efficiency of vaccine DNA delivery in vivo to pigs using dissolvable microneedle patches, in-
tradermal inoculation with needle (ID), surface electroporation (EP), with DNA associated or not to cationic
poly-lactic-co-glycolic acid nanoparticles (NPs). We used a luciferase encoding plasmid (pLuc) as a reporter and
vaccine plasmids encoding antigens from the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV), a
clinically-significant swine arterivirus. Patches were successful at inducing luciferase expression in skin although
at lower level than EP. EP induced the cutaneaous recruitment of granulocytes, of MHC2posCD172Apos myeloid
cells and type 1 conventional dendritic cells, in association with local production of IL-1β, IL-8 and IL-17; these
local responses were more limited with ID and undetectable with patches. The addition of NP to EP especially
promoted the recruitment of the MHC2posCD172Apos CD163int and CD163neg myeloid subsets. Notably we ob-
tained the strongest and broadest IFNγ T-cell response against a panel of PRRSV antigens with DNA+NPs
delivered by EP, whereas patches and ID were ineffective. The anti-PRRSV IgG responses were the highest with
EP administration independently of NPs, mild with ID, and undetectable with patches. These results contrast
with the immunogenicity and efficacy previously induced in mice with patches. This study concludes that
successful DNA vaccine administration in skin can be achieved in pigs with electroporation and patches, but only
the former induces local inflammation, humoral and cellular immunity, with the highest potency when NPs were
used. This finding shows the importance of evaluating the delivery and immunogenicity of DNA vaccines beyond
the mouse model in a preclinical model relevant to human such as pig and reveals that EP with DNA combined to
NP induces strong immunogenicity.
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1. Introduction
Nucleic acid-based vaccine strategies are attractive technologies as
they present a good safety profile due to lack of infectious risk, they are
amenable to rapid, standardized and cost-effective manufacturing
processes, and due to their ease of manipulation, they are adaptable to
emerging pandemic pathogen strains. While RNA vaccines show high
promises due to recent improvement in synthetic mRNA production and
stability [1,2], DNA vaccines remain an important technology [2–4],
considering their good tolerance and safety profile from numerous
clinical trial results, their efficacy in recent human studies [5–8], the
validated high-scale production mode favoring competitive cost, the
existence of five commercialized DNA veterinary vaccines [9,10] and
the high stability outside of the cold chain, an important property for
use in tropical low- and middle-income countries where vaccine need is
particularly high [11]. In the last decade, new developments have im-
proved the DNA vaccine immunogenicity and safety profiles, by opti-
mizing the DNA constructs, targeting vaccine antigens to dendritic cells,
providing adjuvant sequences, and importantly, by improving the DNA
delivery to promote the crossing of the cell and nucleus membrane
taking into account ease of administration and acceptability [2–4].
Among the vaccine DNA delivery methods, electroporation (EP) ap-
pears to have generated the biggest advance in the field [10,12,13]: the
applied current induces pores in the cell membrane and directs the DNA
through the cell towards the positive electrode, and the local in-
flammation, possibly elicited by cell damage, has been associated to the
induction of adaptive immune responses in different species including
mice, pigs and non-human primates [14–17]. Importantly, different EP
devices have been developed to deliver the DNA in muscle and skin
with good results in preclinical models and in clinical trials [10]. The
immuno-competence of the skin with its richness in antigen-presenting
cells and dermal lymphatic vessels, as well as its easy access, make skin
an organ of choice for DNA vaccine delivery. In addition, EP can be
performed at the skin surface and is less invasive and painful as com-
pared to in muscle [13,17]. Yet, EP is coupled to delivery by needle in
skin and it induces discomfort and pain; therefore, other methods,
based on different types of microneedles, have been developed. Mi-
croneedles are sharp micro-projections that pierce the stratum corneum
and deliver vaccines and drugs into skin, without stimulating pain re-
ceptors or affecting blood vessels. Different microneedle patch designs
for DNA delivery include solid [18], coated [19], and lately, dissolvable
microneedles [20,21]. These microneedle-based methods were shown
to be efficient at promoting gene transfer, expression of antigens, and
immune responses in mouse models [18–21]. However, very few stu-
dies document the potency of DNA vaccines delivered by microneedle
patches in larger species [22,23] despite the demonstration of efficient
material and gene transfer in ex vivo cadaver skin [24,25]. To our
knowledge, no studies have examined the immunogenicity of DNA
vaccines delivered by microneedle patches to pigs. Dissolvable micro-
needle patches incorporate the vaccine in their matrix that they release
after skin insertion due to dissolution of the microneedle in the hy-
drated skin tissue, and they are fully biocompatible, stable and easy to
use [21,26]. Interestingly, one of our recent studies showed that dis-
solvable microneedle patches with incorporated trivalent inactivated
influenza vaccine elicited higher and broader immunity compared to
intramuscular injection in mice [27]. In the case of DNA delivery with
dissolvable microneedles, CTL and B cell responses were induced
against papillomavirus antigens in mice [21]. However, the studies
with DNA delivered by microneedle patches were performed in the
mouse model and, although promising, they do not preclude that si-
milar results would be obtained in larger species. Pigs are the most
appropriate animal model for human skin [28] as pig skin shares
structural and histological features with human skin, and we previously
described similarities in the composition of mononuclear phagocyte
subsets [29]. Therefore, pig is a highly relevant preclinical model for
assessments of DNA vaccine delivery strategies in skin both for
translation to human and possible veterinary application for improving
livestock health and welfare.
In this study, we comparatively evaluated different delivery
methods of DNA vaccines in the pig for their efficacy in gene transfer
and immunogenicity. The methods are dissolvable microneedle patches
loaded with DNA (thereafter designated as patches), simple intradermal
(ID) inoculation with needle and surface EP. The DNA vaccine encoded
antigens from a pig arterivirus, the porcine reproductive and re-
spiratory virus (PRRSV) which is the most damaging virus in swine
worldwide [30]. The plasmid DNA was used either as a naked plasmid
or coated on cationic poly-lactic-co-glycolic acid (PLGA) nanoparticles
(NPs), which were previously shown to promote DNA vaccine efficacy
in mice when coupled to microneedles [31] or even to EP [32]. Pre-
vious studies indicated that DNA vaccine immunogenicity results from
the combined effect of gene expression efficiency and local responses,
which are induced by the delivery method as electrical pulses applied
prior to intradermal injection promoted the immune response [16,32].
Therefore, we also evaluated the gene transfer efficiency and the local
inflammation induced by surface EP, simple ID and patches with DNA
combined or not to cationic PLGA NPs in order to get insight into the
parameters involved in immunogenicity. Altogether we found that all
delivery methods, i.e. patches, ID and EP, induced skin cell transfection.
EP, especially when combined to cationic PLGA NPs, triggered sub-
stantial anti-PRRSV B and T cells responses whereas ID only induced
low antibody responses and patches did not induce significant response.
These adaptive responses were associated to local skin responses with
myeloid cell subsets and granulocyte recruitment and cytokine pro-
duction, and suggest that patches lack an immuno-adjuvant effect.
2. Materials and methods
2.1. Antibodies
The anti-pig IFNγ mouse P2G10 mAb (capture) and biotinylated
anti-pig IFNγ P2G11 mAb were from MabTech AB (Nacka Strand,
Sweden). The anti-pig IgA mouse mAb K61e1B4 was bought from Bio-
Rad Antibodies. The anti-pig MHC class II mAb (mouse IgG2a, clone
MSA3), anti-CD172a (mouse IgG2b, clone 74–22–15a) were purchased
from the mAb Center Washington State University (USA). The in-house
produced anti-pig CD13 mAb (mouse IgG1, clone T35) were purified
from mouse ascites using protein A chromatography [33]. The bioti-
nylated mAb anti-human langerin (rat IgG2a, clone 929F3) was ob-
tained from Dendritics (France). Irrelevant unconjugated mouse IgG1,
IgG2a and IgG2b, biotinylated rat IgG2a, Alexa 488-conjugated mouse
IgG2a and PE-conjugated mouse IgG1 (Bio-Rad Antibodies) were used
as isotype controls. The anti-6xHis rabbit polyclonal IgG was purchased
from Abcam. The phycoerythrin (PE)-conjugated anti-CD163 mAb
(mouse IgG1, clone 2A10/11), Alexa 488 (A488)-conjugated anti-
granulocytes (mouse IgG2a, clone 6D10) and A488-streptavidin were
bought from Bio-Rad Antibodies. A647-conjugated goat anti-rabbit IgG
were bought from Jackson ImmunoResearch (USA). A647-conjugated
goat anti-mouse (GAM) IgG2a, EF710 PerCP5.5-conjugated GAM IgG1
and APC-Cy7-conjugated GAM IgG2b were purchased from Fisher Sci-
entific. The horseradish peroxidase (HRP)-conjugated anti-rabbit anti-
body was purchased from Sigma-Aldrich and the HRP-conjugated rat
anti-mouse IgG1 from BD-bioscience.
2.2. Preparation of cationic poly-lactic-co-glycolic acid (PLGA)
nanoparticles (NPs) and coating with DNA
The NPs were prepared as follows: the PLGA RG502H polymer
(Sigma), was dissolved in methylene chloride as a 5% (w/v) solution
and 1ml was emulsified with 0.1 ml of Tris 5 mM pH 7.4 at high speed
using a probe sonicator. The primary emulsion was then added to 5ml
of distilled water containing cetyltrimethylammonium bromide (CTAB)
(0.5%, w/v). The resulting PLGA-CTAB nanoparticles were washed
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once in buffer by centrifugation at 10,000g. After preparation, washing,
and collection, DNA was adsorbed onto the nanoparticles. After opti-
mization, NP:DNA were combined at a 1:20 (μg/μg) ratio for all for-
mulations.
2.3. Production of dissolvable microneedle patches
Dissolvable microneedle patches contained 225 microneedles in a
9 cm2 area (Fig. 1). They were prepared as previously described [27].
DNA (400 μg) was loaded in 73 μl of formulation comprised of 11% (w/
v) trehalose and 1.25% (w/v) polyvinyl alcohol (PVA) as excipients
(5.5 mg/ml DNA concentration). Formulation was delivered directly
onto water-filled microneedle cavities in a polydimethylsiloxane
(PDMS) mould at a rate of 1–3 μl/min. Formulation in the moulds was
dried overnight at room temperature and then pulled from the mould
onto medical grade adhesive tape (1525 L-Poly-Med tape, 3M). A
scoring system was used to grade the physical quality of 1 cm2 patch
units; a patch with a score of 100 reflected a patch where all 25 mi-
croneedles per 1cm2 were perfectly formed. A score of 92 (maximum of
2 missing microneedles) per 1 cm2 was set as the lower limit of ac-
ceptability. The total dose of DNA plasmid, with and without NPs, per
patch, set to 400 μg, was assessed by nanodrop. The quality of the
plasmid in the patches compared to the liquid stock was determined by
agarose gels.
2.4. Construction and production of plasmids
The plasmid encoding porcine GM-CSF (pGM-CSF) has been pre-
viously described [34]. A mCherry encoding plasmid (pmCherry2-N1,
here referred to pmCherry) was obtained from Addgene under MTA. A
firefly luciferase expression plasmid (pLuc) was kindly provided by
Stéphane Biacchesi (INRA, France). The pLuc plasmid includes the
eGFP and firefly luciferase sequences separated by a viral IRES cloned
in a pcDNA3.1 expression vector. pcDNA3.1 vectors encoding for four
PRRSV antigen (PRRSV-AG) sequences from the 13 V091 isolate were
synthetized by GeneArt. The antigen sequences were i) a GP4GP5M
chimera that was derived from [35] and transposed to the 13 V091 viral
sequence (1008 nt), ii) NSP1β (1176 nt), iii) RdRp (1962 nt), and iv) N
(405 nt). In the case of NSP1β and RdRp which are naturally synthe-
tized from viral polyprotein precursors (ORF1 and 2), an exogenous
kozak sequence was added. Only GP4GP5M is expected to be secreted
as it includes the natural leader peptide of GP4. Each antigen sequence
was terminated by a 6xHis tag. The plasmids are named pGP4GP5M,
pN, pNSP1β, and pRdRp. Plasmid productions for immunization were
prepared using Endofree® Plasmid Giga Kits (Qiagen) according to the
manufacturer's instructions and were stored at −20 °C until use.
2.5. Plasmid transfection in vitro
293 T cells were cultivated in DMEM +10% fetal calf serum (FCS).
293 T cells (1.8× 105) were plated and transfected in P12-well plates
with 1 μg of each PRRSV-AG coding plasmid, with a control pcDNA3.1
plasmid encoding for an irrelevant antigen (pcDNA3.1-ctrl), and a
marker plasmid (pmCherry, transfection control) using Fugene HD
(Roche), according to the manufacturer recommendations. After 2 days,
cells were harvested and processed for detection of expressed antigen
by immunofluorescence or Western blot.
2.6. Cell lysate and western blots
Transfected 293 T cells from 2 transfected P12-well plates were
lysed in RIPA buffer 150mM sodium chloride, 1.0% Triton X-100, 0.5%
sodium deoxycholate, 0.1% SDS, 50mM Tris, 5 mM EDTA and a pro-
tease inhibitor cocktail, pH 8.0 at 4 °C. Protein dosage was done with a
Bradford assay against a bovine serum albumin (BSA) standard in RIPA.
Cell lysates (5 μg) were analyzed by Western Blot following a 12% SDS-
PAGE under reducing conditions. Blots were washed with PBS+ 0.05%
Tween 20 and incubated overnight at 4 °C with anti-6xHis rabbit IgG at
a 1:5000 dilution in PBS+ 3% BSA+Tween 0.3% (w/v) followed by
HRP-conjugated anti-rabbit antibody at a 1:100000 dilution in
PBS+3% BSA+Tween 0.3% overnight at 4 °C. Immuno-reactive
bands were visualized with the Clarity Western ECL Substrate (Bio-Rad)
according to the manufacturer's protocol. Image acquisitions were done
with Chemidoc imaging system (Bio-Rad).
2.7. Pig studies
The experiments with the pLuc plasmid (skin cell transduction and
local inflammation) were approved by the COMETHEA ethic committee
under the number 13195–2017120408328722 v2 in accordance with
national guidelines on animal use and performed at the Animal
Genetics and Integrative Biology unit (GABI-INRA), France, under the
accreditation number for animal experimentation C78–719. Large
White pigs (9 pigs, 10 weeks of age) were obtained from INRA UEPR
Rennes-Saint Gilles. The immunization experiments with PRRS-AG en-
coding plasmids was approved by the Comité d'Éthique en
Expérimentation Animale Val de Loire under the number
15051418327338 v10 and were done at the Plate-forme d'Infectiologie
Expérimentale PFIE-INRA, Nouzilly, France (https://doi.org/10.15454/
1.5535888072272498e12) under the accreditation number for animal
experimentation C37–1753 in a A-BSL1 containment. Large White pigs
(46 pigs with 5 for EP optimization and 41 for immunogenicity, 4-week-
old) were obtained from the INRA conventional breeding unit Unité
Expérimentale de Physiologie Animale de l'Orfrasière PAO-INRA,
Nouzilly, France. A first experiment with pLuc plasmid on myeloid cell
recruitment and luciferase expression (data not shown) was conducted
on 6 pigs at PFIE-INRA, under the 15,051,418,327,338 v10 authoriza-
tion, which gave similar results as the one reported here.
2.8. In vivo plasmid transfection for assessment of vector expression and
local inflammation in pig skin
Pigs were anesthetized (2% isofluorane) to avoid animal discomfort
with electroporation (EP) and to optimally control the quality of
Fig. 1. DNA-loaded dissolvable microneedle patches. (A). An image of the array of needles. Each patch was 9 cm2 and comprised of 225 microneedles. (B). An image
of a single microneedle that is 500 μm in height and has a base of 333 μm diameter. DNA was loaded throughout the entire microneedle.
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vaccine administration. Pig skin in the inguinal zone for surface EP, in
the ventral area for ID and in the lower thoracic zone for patch appli-
cation was cleaned with Vetedine soap (Vetoquinol), washed and dried.
The pLuc patches (9 cm2, 400 μg DNA, plain DNA or adsorbed on ca-
tionic PLGA NPs) were placed on the skin under a 20 N force pressure
for one minute. The pig flanks were then wrapped with Elastoplast to
permit the maintenance of the patches on the skin for 24 h. For surface
EP, intradermal injection of pLuc (in 100 μl saline, plain or adsorbed on
NPs) was done in the inguinal zone and EP was performed on the site of
injection using the CUY 21 EDIT system (NEPA Gene, Japan). For ID,
intradermal injections were done in the ventral area. When stated,
pGM-CSF was combined to pLuc (20 μg and 80 μg respectively). Disk
electrodes (10mm) were loaded with conductive gel (Alcyon, France)
and 6 electric pulses were applied during 10ms with 90ms interval.
Trolamine 0.6% (Biafine, France) was spread on the transfected zone
right after administration.
Three groups of 3 pigs were used and designated as group 1, group 2
and Group 3. Group 1 (#4829, 896, 758) received pLuc + pGM-CSF or
pLuc-only in EP and ID injections, Group 2 (#829, 850, 910) received
pLuc-only in patches and EP, Group 3 (#878, 866, 925) received pLuc
+ pGM-CSF in patches. After 24 h, pigs were euthanized and skin
biopsies were collected using an 8-mm diameter disposable biopsy
punch (Kai medical, Japan) after cleaning of the skin with Vetedine
soap and Vetedine 10% solution. Control skin was harvested from the
same zone (inguinal for the EP, ventral for ID, and thoracic zone for the
patches). For evaluation of transfection efficiency, each biopsy was cut
into small pieces and lysed with 150 μl of lysis reagent (Luciferase Assay
System E1500, Promega). Bioluminescence was measured per each
biopsy using the In Vivo Imaging System (IVIS-200, Xenogen, UK) after
adding 100 μl luciferin substrate. A region of interest (ROI) was
manually selected and the intensity of luminescence (photons/s/cm2)
was recorded. For cytokine production assessment, each biopsy was
carefully washed in PBS and placed in RPMI +10% FCS+1% anti-
biotic/antimycotic cocktail for 24 h. For assessment of inflammatory
cell mobilization, 6 biopsies were collected per condition, washed in
PBS, pooled, minced and digested overnight in 6ml RPMI +10%
FCS+ collagenase D (1mg/ml, Roche)+ dispase (0.5 mg/ml,
InVitrogen)+DNAse (0.5 mg/ml, InVitrogen), + antimycotic anti-
biotic cocktail. The skin fragments were gently grinded with a 5ml
plunger through a metal wire mesh and the cell suspension was finally
filtered through 100-μm and 40-μm pores-nylon mesh filters. For his-
tology, skin biopsies from control skin, patch, EP and EP+NP DNA
delivery sites from 3 pigs were fixed in 4% neutral-buffered for-
maldehyde and routinely processed and embedded in paraffin.
Consecutive 4 μm thick sections were cut (3 per block), stained with
hematoxylin-eosin-saffron (HES) and imaged using the caseviewer
software (Sysmex-France, Villepinte, France).
In order to evaluate the voltage per cm (V/cm) parameter leading to
optimal transfection in pig skin, the injected skin areas were subjected
to EP with escalating pulses from 0 to 830 V/cm. in that case, skin was
collected after 48 h. The optimal V/cm was 670 V/cm and was used in
all subsequent experiments (supplementary material 1).
2.9. Staining of cells and flow cytometry analysis
Skin cells from skin biopsy extractions were washed in PBS. A skin
cell fraction was processed for viable cell counts and debris exclusion
using the Guava ViaCount assay and the GuavaSoft module (EMD
Millipore Corporation); this method allowed us to determine the total
cell counts per 6 biopsies. The rest of the skin cells were labeled with
live/dead fixable dead cell kit (405 nm, In Vitrogen). Next, they were
saturated in PBS supplemented with 5% horse serum and 5% pig serum
for 30min and labeled with a mix of primary monoclonal antibodies
(mAb, 2 μg/ml) for 30min, i.e. anti-MHC class II+ anti-
CD172a+ anti-CD13 mAbs followed by EF710-PerCP5.5-conjugated
GAM IgG1+A647-conjugated GAM IgG2a+APC-Cy7-conjugated
GAM IgG2b. After washing, secondary antibodies were saturated by an
excess of mouse IgG1 and IgG2a (50 μg/ml) and finally labeled with PE-
conjugated anti-CD163 and A488-conjugated anti-pig granulocytes
mAb. Appropriate isotype control mAbs were used for fluorescence
minus one controls. In order to detect intracellular langerin, cells were
labeled as described above with anti-MHC class II+ anti-CD172a mAbs
followed by their conjugates, and finally with PE-conjugated anti-
CD163 mAb. After wash, they were fixed and permeabilized using the
Cytofix and Cytoperm kit (Becton Dickinson), and further incubated
with biotinylated anti-langerin or control biotinylated isotype and fi-
nally with A488-streptavidin.
To test the proper expression of the plasmid-coding His-tagged an-
tigens, 293 T cells were harvested after 48-h transfection in 2mM EDTA
and fixed and permeabilized using the Cytofix and Cytoperm kit. They
were then incubated with rabbit anti-6xHis (5 μg/ml) followed by
A647-conjugated goat anti-rabbit IgG. Flow cytometry acquisitions
were done with a LSR Fortessa flow cytometer (Becton Dickinson) and
results were analyzed using FlowJo 10.0.6 software.
2.10. Immunizations and sample collections
Five groups of 7 weaned pigs (28 days-old, 3 or 4 males and 3 or 4
females per group) were immunized as follows: intradermally with DNA
on PLGA NPs (ID+NP), intradermally with naked DNA and surface
electroporation (EP), intradermally with DNA on NPs and surface
electroporation (EP+NP), with patches loaded with DNA and NPs
(patch+NP), and with patches loaded with DNA and NPs and a final EP
boost (patch+NP/EP). A group of 6 pigs were kept as controls. The
electric pulses were set at 670 V/cm and the patches were applied on
the lower thoracic area as described for pLuc above. For the ID+NP, EP
and EP+NP, each PRRSV-AG encoding plasmid (320 μg)+ pGM-CSF
(80 μg) mixed in a final 400 μl volume of 0.9% NaCl was inoculated in 4
intradermal spots (100 μl each) under general anesthesia. Each pig of
the ID+NP, EP, EP+NP and patch+NP group received 3 identical
administrations, 4 weeks apart; the patch+NP/EP received 2 patch
applications and a final EP boost, 4 weeks apart. Sera were harvested on
D0, 35, 64, 84. Nasal swabs from the 2 nostrils were collected in
PBS+ anti-protease cocktail at D0 and 84. Spleen was harvested on
D84 and spleen cells were collected as described [36]. At the end of the
study, the animals were euthanized by an overdose of sodium pen-
tothal.
2.11. Overlapping peptides
Overlapping peptides (20 mers, offset by 8 amino-acids) covering
the NSP1β, RdRp, N and the GP4GP5M PRRSV antigens were synthe-
tized by Mimotopes (Mimotopes Pty Ltd., Victoria, Australia, http://
www.mimotopes.com). Upon receipt, the peptides were diluted in
H2O:acetonitrile (50:50 vol:vol) at a 5mg/ml concentration and
grouped as pools of peptides not exceeding 25 peptides: pool N (15
peptides), pool GP1 (from peptide1 to 20 of the GP4GP5M chimera),
pool GP2 (from peptide 21 to 40 of the GP4GP5M chimera), pool
NSP1β1 (from peptide 1 to 22), pool NSP1β2 (from peptide 23 to 47),
pool RdRp1 (peptide 1 to 20), pool RdRp2 (peptide 21 to 40), pool
RdRp3 (peptide 41 to 60), pool RdRp4 (peptide 61 to 80). A 20-mer
peptide from the HIV polymerase was used as control.
2.12. Evaluation of PRRSV-AG-specific T cell responses by ELISPOT
IFNγ-secreting T cells were detected using PVDF membrane-bot-
tomed 96-well plates (Multiscreen®HTS, Millipore) coated with 15 μg/ml
anti-porcine IFNγ (capture mAb) in PBS. Spleen cells were suspended in
X-VIVO-20 medium supplemented with 2% FCS, 100 U/ml penicillin
and 1 μg/ml streptomycin (culture medium) and 2×105 were plated
per well. Cells were stimulated with the different pools of overlapping
peptides described above at a 5 μg/ml final concentration for 18 h, in
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duplicates. A HIV polymerase-derived peptide and ConA at 25 μg/ml
were used as controls. Control wells with H2O:acetonitrile were done.
After 18 h, the IFNγ-secreting cells were revealed by sequential in-
cubations with 0.5 μg/ml biotinylated anti-IFNγ followed by 0.5 μg/ml
alkaline phosphatase conjugated-streptavidin and 1-Step™ BCIP/NBT
reagent. The spots were enumerated using the iSPOT reader from
Autoimmun Diagnostica GmbH. Positive wells were considered if the
spot numbers in the 2 PRRSV stimulated conditions were strictly su-
perior to the spot numbers in the control peptide stimulated conditions
as described [37]. The mean number of spots of stimulated minus
control peptide was calculated.
2.13. Evaluation of anti-N IgG and IgA by ELISA
The sera and swab extracts were assayed using the Ingezim PRRS
2.0 kit (Ingenasa, Spain) at a 1:40 and 1:2 dilution respectively. S/P
ratio were calculated as follows: [OD sample minus OD negative con-
trol]:[OD positive control minus OD negative control]. For IgA, area flat
bottom polystyrene high bind microplates (Corning) were coated
overnight at 4 °C with 50 ng N recombinant protein (same preparation
as in the Ingezim PRRSV 2.0 kit) in 50 μl of PBS. Plates were saturated
with 0.1% skim milk in PBS - 0.05% Tween 20 for 2 h at 37 °C. Samples
were 2-fold serially diluted and were incubated for 2 h at 20 °C. N an-
tigen-bound IgA were detected using anti-pig IgA mAb (50 ng/ml) fol-
lowed by HRP-conjugated rat anti-mouse IgG1 (500 ng/ml). All detec-
tion antibodies were incubated for 1 h at 37 °C. The 1-Step™ ULTRA-
tetramethylbenzidine HRP substrate (TMB, Thermo-Scientific) was used
and absorbance was measured at 405 nm.
2.14. Cytokine detection
Concentrations of IL-1β, IL-17 and IL-8 were assessed by cytometric
beads assay for simultaneous detection of 12 swine cytokines (IL-4,
IFNα, TNFα, IL-2, IL-8, IL-13, IL-12, IL-6, IFNγ, IL-10, IL-17, IL-1β) as
described [38].
2.15. Statistical and correlation analysis
Data were analyzed with the GraphPad Prism 6.0 software. The
unpaired non-parametric bilateral Mann-Whitney test was used to
compare the efficacies of different V/cm and of delivery methods for
induction of luciferase expression, the innate cytokine secretion and the
IgG content in sera and swab extracts. The Wilcoxon signed rank test
was used to compare the T cell response versus the non-vaccinated
group.
3. Results
3.1. Formulating DNA plasmids with nanoparticles (NPs)
A previous work in the pig [39] identified that 400 μg DNA was an
optimal DNA amount to immunize pigs, what we recently confirmed in
sheep [37], therefore we selected this dose for all the delivery methods
in this work. The coating of the DNA on cationic PLGA NPs aimed at
promoting DNA stability in extracellular fluid and during the in-
tracellular trafficking to the nucleus as well as at favoring the capture
by skin cells including mononuclear phagocytes for antigen presenta-
tion [10,31]. Patch fabrication requires a concentrated formulation of
5.5 mg/ml DNA, associated with NPs, to be dispensed into a small vo-
lume of the microneedle mould. In initial testing, we determined that a
20:1 ratio of DNA:NPs was the best ratio for optimal loading of DNA on
NPs without precipitation occurring. By measurement of free DNA
(non-adsorbed to the NPs) in the formulation supernatant after cen-
trifugation, we found that 15–20% of the total DNA was loaded on the
NPs in this condition, in agreement with the high proportion of DNA vs
NPs. The NPs coated with DNA at a 20:1 ratio measured between 120
and 140 nm and had a polydispersity index around 0.4. DNA adsorption
onto the surface of the cationic NPs were also indicated by a drop of the
zeta potential (from +15/+30mV to −30/−50mV).
3.2. Patches loaded with plain DNA or DNA combined to cationic PLGA
NPs
We incorporated 44 μg of DNA plasmid per cm2 patch, which is in
the same order of magnitude as in previous studies where 50 μg DNA
per cm2 were used [19,22]. These patches contained 225 needles each
(Fig. 1A), the needles were 500 μm high (Fig. 1B), and the total amount
of DNA (plain DNA or associated to NPs at a 20:1 ratio) was 400 μg per
9 cm2 patch. The quality of the patches was high, as reflected in the
quality score reaching 100% (see Material and Methods). The patches
were applied to the lower thoracic zone to permit a 20 N force to be
applied for 1min to the skin and as a convenient site for securely pla-
cing the patch and an Elastoplast wrap. This skin thickness in this zone
is between 90 and 135 μm (not shown) and is therefore compatible with
vaccine delivery through the epidermis with 500 μm-high needles. We
previously characterised skin penetration events that occur in ex vivo
pig skin with dissolvable microneedle patch administration, including
with histological analyses [24,40].
3.3. Transduction efficacy of pig skin cells upon DNA delivery with patches,
ID and surface EP
In order to evaluate the in vivo transfection efficacy of DNA plas-
mids delivery, we administered a plasmid encoding for a reporter lu-
ciferase gene (pLuc) using patches as well as the intradermal route (ID),
or the ID route plus surface electroporation (EP), with plain DNA or
DNA combined to cationic PLGA NPs. The optimal plasmid delivery V/
cm parameter for EP had been established beforehand on test pigs,
using escalating electric field values. A plateaued luciferase signal that
did not induce local necrosis was obtained with the 670 V/cm para-
meter (Supplementary material 1) which was used for all the surface EP
in this paper. A group of 3 pigs was used for ID administration in the
ventral zone and EP in the inguinal zone (group 1), and another group
of 3 pigs for patch administration in the lower thoracic zone and for EP
in the inguinal zone (group 2) (Fig. 2A). A 100 μg DNA dose was chosen
for EP and ID based on our previous successful gene transfer study in
sheep skin using surface EP [37]. Skin biopsies were harvested after
24 h and processed for detection of luciferase expression by biolumi-
nescence measurement. This timing was selected as shown to be op-
timal by others [41]. Control skin from the same thoracic (CtD for
control patch), ventral (CtI for control ID) and inguinal zones (CtE for
control EP) was collected, because different skin zones can differ in
their intrinsic luminescence, in cell composition and in other biological
properties. The level of bioluminescence induced by the ID route was
significantly higher than the ventral control (2.8× 106 ± 2.63× 106
vs.. 5.62×105 ± 7.05×105 p/cm2/s/r, p < .05), and the level in-
duced by EP was clearly higher than the ID one's (group 1,
1.71×108 ± 1.87× 108, p < .01) (Fig. 2B). The signal with patches
loaded with plain DNA was also significantly higher than the thoracic
control and reached 2.89× 107 ± 1.88×107 p/cm2/s/r in group 2,
and EP delivery induced further higher levels, reaching
1.3×108 ± 1.46× 107 p/cm2/s/r in that group (p < .01, EP vs.
patches). Coating NPs with DNA did not statistically change the level of
bioluminescence in all 3 delivery methods (Fig. 2B). The comparison of
transfection efficiency levels between ID and patches was not done from
these results because ID and patch applications were not performed on
the same pigs. In conclusion, skin cell transduction can be obtained
with DNA-loaded patches as well as with ID delivery, although with
lower efficacy than with EP, and the level of transduction does not
significantly improve by loading the DNA on cationic PLGA NPs in our
conditions.
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3.4. Inflammatory cell mobilization induced by DNA delivery with patches
and surface EP in skin
The immunogenicity of plasmid DNA vaccines has been shown to be
associated both to cell transduction and to inflammatory cell mobili-
zation, which has been proposed to have an adjuvant effect [15–17].
We therefore analyzed the mononuclear phagocyte and granulocyte cell
types in skin biopsies 24 h after administration of plasmid with patches,
ID or EP, with plain DNA or combined to cationic PLGA NPs. In order to
relate these results to the immunogenicity experiment where pGM-CSF
was used as a genetic adjuvant (see below), pLuc was combined to
pGM-CSF (4:1, μg:μg ratio). The mononuclear cell subsets were iden-
tified based on our previous work on swine skin dendritic cells and
macrophages [29,42] and on others [43]. The gating strategy is de-
scribed in Supplementary material 2 on cells from control skin (A) and
surface EP (B) biopsies. Granulocytes were identified as 6D10pos cells.
From our previous work [29,42], CD172AposCD163high were split in
MHC class IIpos and neg, corresponding to CD163high dermal DCs (DDCs),
homologous to human CD14pos DDCs, and CD163high macrophages
(MPs) respectively. Among CD163int/neg MHC class IIpos cells, we dis-
tinguished CD172AnegCD13pos cells which correspond to the conven-
tional type 1 DC (cDC1) in human, mice and pigs [43–45]. These cells
back-gate to MHC class IIhigh cells (supplementary material 2), as ex-
pected, both in the control and EP conditions [29,42]. Among CD163int/
neg MHC class IIpos cells, we also distinguished CD172AposCD163neg and
CD172AposCD163int cells. In the control condition, the CD163int cells
back-gate mainly to MHC class IIhigh cells and the CD163intMHC class
IIhigh cells correspond to cDC2 DC, homologous to human CD1a dermal
DC [29,42]. The CD163neg cells back-gate mainly to MHC class IIhigh
cells and a large fraction of them express high levels of langerin (sup-
plementary material 3) and correspond to Langerhans cells (LCs)
[29,42]. However, upon EP, CD163int and neg cells expressed variable
MHC class II among which the MHC class IIhigh cells cannot be
distinguished. Furthermore, langerin expression is much reduced upon
EP (supplementary material 3). Therefore, we will designate these 2
subsets as CD163int and CD163neg cells which are likely to correspond
to heterogeneous populations of inflammatory monocytic cells mixed
with cDC2 and LC respectively. Based on this gating, we analyzed the
percentage of each subset among live cells (supplementary material 4)
and the total live cells of each subset in a pool of 6 biopsies upon pLuc
+ pGM-CSF delivery, in 2 groups of pigs (Fig. 3A): group 1 (EP and ID)
and group 3 (patch). The percentage of live cells were not significantly
affected by EP (supplementary material 4) and the total live cell
numbers in biopsy pools slightly varied between conditions, with the
lower numbers found in the inguinal controls (Fig. 3B). Compared to
control skin, ID and EP induced increased numbers of granulocytes, of
MHC class IIpos CD163int and CD163neg cells, and EP had the strongest
effects on these subsets recruitment, promoting also cDC1 accumulation
(Fig. 3B). Cationic PLGA NPs combined to EP tended to enhance the
recruitment of these different subsets, and especially of the MHC class
IIpos CD163int and CD163neg cells (Fig. 3B). The increase in proportion
(%) of these subsets' representation followed the same trend as their cell
numbers in biopsy pools (supplementary material 4). Only the pro-
portion of CD163high DDC and MP appeared to decrease with EP, sug-
gesting that these later subsets are not or minimally recruited by EP
(supplementary material 4). Conversely, patch application did not re-
sult in change in mononuclear phagocytes nor granulocytes re-
presentation (Fig. 3B, supplementary material 4). A histological ex-
amination was conducted 24 h after administration of DNA with patch
and EP and confirmed the accumulation of inflammatory cells locally
upon EP, both in the epidermis and dermis, whereas there was no de-
tectable inflammation with patches (supplementary material 5). Alto-
gether these results show that ID and EP induced the recruitment of
inflammatory myeloid cell subsets whereas patches did not. EP+NP
further enhanced inflammatory cell accumulation, especially of the
MHC class IIhigh CD163int and CD163neg subsets.
Fig. 2. Expression of luciferase activity upon in vivo
transfection of pig skin cells with pLuc delivered
using surface EP, ID and patch applications. (A).
Large White pigs (Group 1: #4829, 896, 758 and
Group 2: #829, 850 and 910) were anesthetized (see
Material and methods). Group 1 received pLuc with
EP and ID administration, Group 2 received pLuc
with EP and patches. Each pig is represented by a
distinct symbol (see legend on the figure). In the
inguinal zone, 100 μg pLuc, either plain or adsorbed
on cationic PLGA NP (20:1, DNA:NP ratio) was in-
jected ID and the skin site was subjected to surface
EP as described in the material and methods (EP and
EP+NP). In the ventral zone, 100 μg pLuc, either
plain or adsorbed on cationic PLGA NP was injected
ID. In the thoracic area, patches loaded with pLuc
plasmid (400 μg per 9 cm2 patch), either plain or
adsorbed on cationic PLGA NP (20:1, DNA:NP ratio)
were applied on the skin as described in the material
and methods (patch and patch+NP). (B). After 24 h,
8 mm biopsies were harvested at the sites of ad-
ministration and processed for luciferase activity
detection. Control skin of the same respective sites
(CtE for EP control, CtI for ID control, and CtD for
patch control) were collected and treated in parallel.
The luciferase activity results (p/s/cm2/sr) of the
transfected and control skin from each pig are in-
dicated by a distinct symbol and were obtained from
independent duplicates. Significant differences be-
tween the injected sites and their respective control
sites were determined with the non-parametric
Mann-Whitney test (**, p < .01; *, p < .05).
Similar results were obtained in an independent ex-
periment.
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3.5. Inflammatory cytokine synthesis in skin upon DNA delivery with
patches and surface EP
In order to further analyse the inflammation induced by the dif-
ferent DNA delivery methods, we harvested skin biopsies 24 h after
pLuc +pGM-CSF administration and placed 2 biopsies per condition in
flotation in 2 separate wells of culture medium for 24 h. The cytokine
content was analyzed in a multiplex assay for the detection of 12 cy-
tokines (IL-4, IFNα, TNFα, IL-2, IL-8, IL-13, IL-12, IL-6, IFNγ, IL-10, IL-
17, IL1β). Surface EP, with or without cationic PLGA NPs, induced the
secretion of IL-1β, IL-8, and IL17, but not of the other cytokines (Fig. 4).
DNA delivered by patches did not induce detectable cytokine synthesis
under these conditions (Fig. 4). Similar results were obtained when
pLuc only (without GM-CSF) was used for the delivery with EP (sup-
plementary material 6). Therefore, the delivery of DNA with patches
allows gene transfer and expression in skin cells without detectable
inflammatory response, whereas surface EP induces high reporter gene
expression, inflammatory cell mobilization, and inflammatory cytokine
expression.
3.6. Immune responses induced by DNA vaccine delivery with patches, ID
and surface EP
The next step was to evaluate the immunogenicity induced by the
DNA delivery with patches, ID and EP. We produced plasmids encoding
for antigens from PRRSV, a swine arterivirus. Four antigens were se-
lected based on their T and B cell antigenicity: N is the im-
munodominant B cell antigen, and GP4GP5M, RdRp and NSP1β include
conserved T cell epitopes across distant viral strains [46,47]. The
PRRSV antigens (PRRSV-AG) sequences were end-terminated by a
6xHis tag and cloned in a pcDNA3.1 expression vector. The 4 PRRSV-
AG vectors were transiently transfected in 293 T cells and the 6xHis-
tagged proteins were detected intracellularly by immunostaining and
flow cytometry (Fig. 5A) and after cell lysis in RIPA buffer by Western
Blot (Fig. 5B). Despite the known difficulty to detect 6xHis-tagged
proteins due to histidine stretch content in cellular proteins, we could
well detect the transfected PRRSV-AG, as compared to cells transfected
with a control pcDNA3.1 vector (Fig. 5A and B). The 4 antigens were
detected at expected MW sizes, although additional products were
found possibly due to incomplete reduction or alternative codon usage,
but in coding frame as 6xHis-tag terminated. These PRRSV-AG
Fig. 3. Myeloid cell mobilization upon administration of pLuc and pGM-CSF delivered in skin using surface EP, ID and patch applications. (A). Large White pigs
(Group 1: #4829, 896, 758 and Group 3: #878, 866 and 925) were anesthetized. Group 1 received pLuc + pGM-CSF with EP and ID administration, Group 3 received
pLuc + pGM-CSF with patches. Each pig is represented by a distinct symbol (see legend on the figure). For this experiment, pGM-CSF was combined to pLuc (20 μg
pGM-CSF+ 80 μg pLuc in EP and 80 μg pGM-CSF+ 320 μg pLuc in patches). (B). Six EP and ID sites were pooled per condition and 6 biopsies were pooled from
patch sites and the biopsies were processed to skin cell dissociation as described in the material and methods. The total live cell number from the 6 biopsies, obtained
with the Guava ViaCount assay, are reported. The total live cell numbers for each indicated subset in the 6 biopsies are shown. The delivery methods are named as in
Fig. 2. The cell subset % among live cells are provided in supplementary material 4. No statistical test was conducted due to the< 5 values per condition; 6 biopsies
were used to generate each value, with pairs between treatments and controls. Similar results were obtained in an independent experiment.
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Fig. 4. Inflammatory cytokine secretion upon ad-
ministration of pLuc and pGM-CSF delivered in skin
using surface EP and patch application. The pLuc +
pGM-CSF plasmids were administered by EP and ID
injections in group 1 and by patches in group 3 as
described in Fig. 3. Twenty-four hours after, skin
biopsies from 2 same administration types were
aseptically collected, washed in PBS and placed in
1ml RPMI +10% FCS+1% antibiotic/antimycotic
cocktail for 24 h. Cytokines were detected using a
multiplex cytometric bead assay and the cytokine
concentration was evaluated using a standard curve
with recombinant cytokines. The cytokine con-
centration of biopsies from each pig are indicated by
a distinct symbol. Significant differences between
the injected sites and control sites were determined
with non-parametric Mann-Whitney test (**,
p < .01; *, p < .05). (A). IL-8. (B). IL-1β. (C). IL-
17. The bars represent the means.
Fig. 5. PRRSV antigen expression in 293 T cells. 293 T cells were transfected with pcDNA3.1-ctrl or with pGP4GP5M, pN, pNSP1β, and pRdRp. After 2 days, cells
were either processed to intracellular detection (A) or lysed in RIPA buffer (B). (A). PRRSV-AG terminated with 6xHis tag were detected, following 293 T cell
permeabilization, with anti-6xHis rabbit polyclonal IgG followed by A647-conjugated goat anti-rabbit IgG. The 6xHis tag signal in each pPRRSV-AG transfected 293 T
cells (grey background) is overlaid on the signal from pcDNA3.1-ctrl transfected 293 T cells and processed in parallel (dashed line). (B). A Western blot was done
using anti-His rabbit IgG followed by HRP-conjugated anti-rabbit antibody. The samples (5 μg total protein) were migrated on the same SDS-PAGE gel under
denaturing conditions. The bands at the expected theoretical molecular weight of each PRRSV protein are indicated with an arrow (N: 16 kDa, GP4GP5M: 37 kDa,
NSP1b: 47 kDa and RdRp: 77 kDa). Note that no background is detected from the lane of 293 T cells transfected with pcDNA3.1-ctrl (CTRL lanes).
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encoding vectors were therefore suitable to provide PRRSV B and T cell
epitopes. Pigs were then immunized with 320 μg of these vectors, each
combined with 80 μg pGM-CSF in 5 vaccinated groups and one non-
vaccinated control group. The vaccinated groups (7 pigs in vaccinated
groups initially, 6 in the control group) included: a group receiving
DNA with cationic PLGA NP directly injected in the dermis (ID+ NP), 2
groups receiving plasmids intradermally followed by surface EP with
naked DNA (EP) and DNA adsorbed on cationic NPs (EP+NP), a group
receiving DNA delivered by patches with cationic PLGA NPs (patch
+NP), and finally a group primed twice with patches (DNA with NPs)
and finally boosted with naked DNA and EP (patch+NP/EP) (Fig. 6A-
B). There was one dead pig in the EP and ID+NP groups, due to
Fig. 6. Detection of IgG in sera and nasal secretions from pigs immunized with pPRRSV-AG delivered using surface EP, ID and patches. (A and B). Schematic
representation of the immunization protocol of pigs with pPRRSV-AG+pGM-CSF. (A) Each pig received 320 μg of each pPRRSV-AG combined to 80 μg pGM-CS on
day (D)0, D35 and D64 (see material and methods and B). Sera were collected at D0, D35, D64, D84, nasal swab at D0 and D84 and spleen cells were collected at D84.
(B). Table is summarizing the 6 different vaccinated groups. Intradermal inoculations of plasmid coated on cationic PLGA NPs (ID+NP group), intradermal in-
oculations of plain DNA followed by EP (EP group), intradermal inoculations of plasmid coated on cationic PLGA NPs followed by EP (EP+NP group), or plasmid on
NPs delivered by patch applications (patch+NP group) were performed on D0, D35 and D64. In the case of the patch+NP/EP group, plasmid DNA was delivered
with patch+NP on D0 and D35 and with intradermal inoculation + EP on D63. (C-E). The sera (1:40) from D35 (C), D64 (D) and D84 (E) were assayed for detection
of anti-N IgG using the Ingezim PRRS 2.0 kit. S/P ratios were calculated as described in the Material and Methods. (F). Nasal swab extracts (1:2) were assayed for
detection of anti-N IgG using the Ingezim PRRS 2.0 kit on D84. Significant differences between the vaccinated groups and the control group were determined with the
non-parametric Mann Whitney test (* p < .05, **, p < .01).
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anesthesia. The anti-N IgG levels were assayed from sera and nasal
swab extracts using a commercial kit. Anti-N IgG were detectable at 35
and their levels further increased at D64 and D84, both in the EP and
the EP+NP groups, and not in the patch groups (Fig. 6C-E). Low but
significant anti-N IgG amounts were detected at D84 in ID+NP groups
(Fig. 6E). No effect of DNA adsorption on cationic NP was observed on
the anti-N IgG response in the EP conditions (Fig. 6C-E). Low levels of
anti-N IgG were detected in nasal swab extracts in the EP and EP+NP
group (Fig. 6F). Anti-N IgA could not be detected at D84, neither in sera
nor in swab extracts.
The splenocytes were re-stimulated with overlapping peptide pools
from the PRRSV-AG and the IFNγ-secreting cells were detected (Fig. 7A,
Table 1). Nine pools of maximum 25 peptides were used in order to
stimulate splenocytes with 1 μg of each peptide per well without toxi-
city (see Material and Methods). Non-specific responses in control pigs
were obtained with the GP2 and NSP1β pools, possibly due to cross
reactivity of the TCR with unrelated T cell epitopes to which these pigs
have been exposed, therefore these pools were not considered in the
analysis. No antigen was highly dominant compared to the other anti-
gens; each animal demonstrated a unique hierarchy of antigen re-
cognition, irrespective of vaccine. However, N, RdRp1 and RdRp4 in-
duced the most consistent responses across pigs and vaccine regimens.
A Wilcoxon signed rank test reveals statistically significant differences
between the response magnitudes in the EP+NP and the control group
in the case of the RdRp1 and RdRp4 pools, and close to significance
with the N and RdRp2 pool (Fig. 7A). Fig. 7B shows a stack bar plot of
the responses to peptide pools per pig and illustrates that the breadth
and magnitudes of the IFNγ responses are higher in the EP+NP groups
vs the other groups. For each pig, the number of peptide pools able to
stimulate splenocytes was calculated and the proportion of pigs capable
to respond to> 2 peptide pools was 0/6 in the control group, 1/6 in the
ID+NP, 1/7 in the patch+NP/EP group, 2/7 in the patch+NP group,
4/6 in the EP group and 5/7 in the EP+NP group (Table 1). Altogether
this immunogenicity analysis shows that DNA delivery with patches
induced no significant B and T cell responses, DNA delivery with ID
induced low but significant B cell responses, whereas delivery with EP
induced substantial IgG responses in all pigs and DNA adsorption on
cationic PLGA NPs combined to EP promoted the magnitude and
breadth of the IFNγ T cell responses.
4. Discussion
DNA delivery with dissolvable microneedle patches is an emerging
technology with advantages such as elimination of needles and ha-
zardous waste, improved vaccine thermo-stability, potential dose-
sparing capacity and self-administration. However, it was unknown if
the potency of a DNA vaccine can be enhanced by patch delivery into
the skin in a relevant preclinical model such as pigs. In this work, we
evaluated DNA delivery by patches compared to simple ID and EP in the
pig via skin. We found that, although plasmid DNA was expressed in
skin upon patch application, no significant T and B cell responses were
induced to the PRRSV-AGs, whereas simple ID induced mild but sig-
nificant B cell responses and EP induced higher IgG and IFNγ-T cell
responses, especially when DNA was combined to cationic PLGA NPs.
We also found that patches, with DNA combined or not on cationic
PLGA NPs, did not induce detectable local innate response whereas
simple ID and especially EP did induce substantial local inflammatory
responses. These results show that the combination of transfection ef-
ficiency with local innate immune responses (myeloid cell recruitment
and cytokine expression) is associated with immunity induced by DNA
delivery methods. This finding suggests avenues for improving the
immunogenicity of patches by addition of innate immunity stimulants
in pigs and likely in humans.
The pig is considered as the preclinical model of choice by the sci-
entific community and health authorities to evaluate the efficacy and
toxicity of drug delivery through skin as well as to study wound healing
mechanisms [48]. Anatomical, physiological and immunological prop-
erties of pig skin also support the pertinence of this animal model for
assessing needle-free vaccine delivery [49]. Indeed, pig and human skin
share the same general structure, thickness, hair follicle content,
Fig. 7. Detection of IFNγ-secreting cells in spleen from pigs immunized with pPRRSV-AG delivered using surface EP, ID and patches. Splenocytes
(2.5×105) were plated in Multiscreen plates coated with a capture anti-porcine IFNγ mAb (duplicated wells) and re-stimulated for 18 h with 5 μg/ml of peptide
pools made of< 25 overlapping peptides covering the N, pool GP1 (from peptide 1 to 20 of the GP4GP5M chimera), pool RdRp1 (peptide 1 to 20), pool RdRp2
(peptide 21 to 40), pool RdRp3 (peptide 41 to 60), pool RdRp4 (peptide 61 to 80). An irrelevant peptide (5 μg/ml) or plain medium were used as controls. IFNγ spot
forming cell (SFC) counts were considered PRRSV-AG-specific when both duplicated well values from cells stimulated with PRRSV peptides were strictly superior to
the duplicated-well values from cells stimulated with the irrelevant peptide. (A) The mean SFC number in stimulated wells minus the ones with irrelevant peptide
wells are shown per pig for each peptide pool (net mean values). Each symbol in the graphs represents an individual animal and the same symbol is used across the
peptide pool restimulation. The box plot is drawn on the mean values obtained with the different pigs. Significant differences between the vaccinated groups and the
control group were determined with the non-parametric Wilcoxon test (*, p < .05). (B) The net IFNγ SFC numbers upon stimulation is compiled for all peptides in
each sheep, showing the breadth and the magnitude of the response.
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pigmentation, collagen and lipid composition, by opposition with ro-
dents [50]. In addition, the immune and inflammatory responses of
human and pigs are closer to each other than to the rodent ones [51].
Furthermore, the immune and inflammation-related gene families ex-
panded or contracted with similar rates during human and pig evolu-
tion but with much higher rates than in rodents, and the structural
functional protein-domain of orthologous immune and inflammation-
related genes show a higher degree of preservation between human and
pig than between these species and rodents [52] [53]. This convergent
genetic evolution might be related to shared selection pressures by the
same families of pathogens such as intestinal worms and by zoonotic
agents such as influenza, rotavirus, Campylobacter, Toxoplasma gondii
etc. [54]. Correlatively pig and human macrophages present similar
genomic responses during M1 polarization upon LPS stimulation,
whereas mouse macrophage genomic response appears more distant
[52,55,56]. Our group also showed that pig and human skin display
similar subsets of dendritic cells and macrophages in the epidermis and
dermis, based on comparative transcriptomes and functional analyses
[29]. Therefore, pig presents skin tissue and immune characteristics
more relevant than the rodent ones for prediction of efficacy of needle-
free delivery of vaccines such as DNA vaccines with patches in human.
Significant transduction of skin cells in pigs was obtained with
patches as previously published in mice with DNA and viral vectors
[21,26,40]. However, in contrast with other studies using solid micro-
needle in mice [31,57], we did not measure a benefit of DNA combi-
nation to cationic PLGA NPs in terms of transgene expression at 24 h.
This may highlight difference in potency of DNA vaccines in mice
compared to larger animals. This difference may also be due to using
net negatively charged DNA-conjugated particles, whereas net posi-
tively charged plasmid DNA-cationic NP complexes were shown to be
the most favorable to immunogenicity [31]. In addition, as explained in
the result section, only about 15–20% of DNA is adsorbed on cationic
PLGA NPs, therefore most of the DNA is naked in our formulations and
this excess of free DNA may explain the lack of detectable benefit of NPs
in transgene expression. It is also possible that the NP benefit would be
obtained at a later time point than 24 h, considering the expected in-
crease in stability of DNA associated to NPs. The DNA load in patches is
44 μg/cm2 patch, therefore a skin biopsy (0.5 cm2) corresponds to a
theoretical delivery of 22 μg DNA whereas in the case of EP, the biopsy
roughly corresponds to the whole delivery of 100 μg DNA. Therefore, it
is possible that the efficiency of gene transfer by patch per μg DNA is
pretty high, although escalating doses should be used with both de-
livery methods in order to make a conclusive statement. It is also pos-
sible that the transfected cell types in skin are different between the
different methods. In the case of surface EP, the dominant transduced
cell types vary between studies, and were identified as keratinocytes,
fibrocytes, dendritic-like cells, adipocytes or myocytes, possibly due to
differences in the investigated species and in the precise site of injection
in the dermis [17,58,59]. The transduced cells have not yet been
identified in the case of dissolvable microneedle patches, to the best of
our knowledge. Cell localization studies involving refined imaging
technologies such as cleared in-toto tissue and confocal microscopy
Table 1
IFNγ-secreting T cells in the pPRRSV-AG vaccinated groups upon re-stimulation with overlapping peptide pools (N, GP1, RdRp1, RdRp2, RdRp3, RdRp4).
Vaccine Pig N° Peptide pools Nb of stimulating peptide pools/pig % responding pigs to > 2 peptides/group
N GP1 RdRp1 RdRp2 RdRp3 RdRp4
None 6 0 0 0 0 0 0 0 0/6
44 0 0 0 0 0 0 0
48 0 0 0 22 0 17 2
55 0 0 40 0 0 0 1
57 0 0 0 0 0 0 0
78 0 0 0 0 0 0 0
EP 13 10 8 5 11 21 13 6 4/6
17 0 0 0 0 0 0 0
38 5 0 5 29 10 23 5
39 10 0 0 24 11 24 4
67 0 0 25 10 0 0 2
68 0 0 0 24 13 30 3
EP+NP 7 39 11 15 16 0 34 5 5/7
37 19 0 51 11 12 43 5
46 0 0 0 0 0 7 1
47 0 0 13 0 0 10 2
59 10 0 12 10 0 30 4
72 36 11 41 61 55 71 6
76 37 32 24 37 19 12 6
ID+NP 10 0 0 0 0 0 0 0 1/6
36 0 0 0 0 0 0 0
45 0 0 23 0 33 34 3
71 0 35 0 27 0 0 2
75 0 0 0 0 0 0 0
77 0 19 14 0 0 0 2
Patch+NP 2 0 0 7 7 0 6 3 2/7
12 0 0 7 7 0 15 3
16 0 0 0 0 0 0 0
25 0 0 0 0 0 30 1
35 0 0 0 15 0 0 1
53 0 0 30 0 0 0 1
58 0 0 0 0 0 0 0
Patch+NP/EP 11 0 0 0 24 0 0 1 1/7
14 0 0 0 0 18 27 2
23 0 0 43 0 0 55 2
54 0 0 0 0 0 0 0
56 0 0 9 17 12 17 4
65 0 0 26 0 0 0 1
74 0 0 0 0 0 0 0
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with suitable reagents will be needed to reliably assess the in vivo
transfected cell type and their location in the skin or elsewhere [60]. It
is also possible that DNA combination with PLGA NPs alters the cell
type that capture the DNA, and favors cells endowed with higher
macropinocytosis capacities, especially after the EP pulses.
Efficient immunogenicity of DNA vaccination has been previously
related to inflammatory cell mobilization induced by the delivery
method [16,17]. In monkey, surface EP was shown to induce the ac-
cumulation of granulocytes and of MHC class IIpos antigen-presenting
cells expressing variable levels of CD163 [17]. In our pig experiment,
we confirm the strong accumulation of granulocytes upon surface EP
and of different types of MHC class IIpos cells, i.e. cDC1, CD163neg and
CD163int subsets (Fig. 3). As explained in the results, the exact identity
of the last two subsets could not be determined and they probably
correspond to heterogeneous populations of inflammatory CD172Apos
monocytic cells and LC (CD163neg) and cDC2 (CD163int). The precise
assignment of MHC class IIpos CD172Apos cells to a defined subset under
inflammatory conditions cannot be done currently with multi-para-
meter flow cytometry, not only in pigs, but also in the reference mouse
and human species [61]. Such an assignment requires sophisticated
analyses, such as comparative transcriptome at the single cell level, due
to still blurry phenotypes of MHC class IIpos CD172Apos subsets [62–64].
Of note, NPs added to EP tended to further enhance the recruitment of
inflammatory cells and especially of the MHC class IIpos CD163int and
CD163neg subsets. Further insight in the composition of these cell po-
pulations would be of interest to understand the adjuvant effect of NPs
in our setting.
Together with the inflammatory cell mobilization, we found that EP,
with and without PLGA NPs, induced the synthesis of IL-8, IL-17 and IL-
1β. IL-8 and IL-17 are involved in immune cell recruitment and IL-1β is
recognized as an important cytokine that is released in response to
cellular stress and damage associated molecular patterns and which
effectively activates antigen presenting cells and adaptive immunity
[65]. Patches, with and without NP, did not induce detectable in-
flammatory cell mobilization nor inflammatory cytokine secretion. We
also previously demonstrated significantly reduced cytokine induction
when vaccines were administered to mice using silicon microneedle
arrays compared to ID delivery [66,67]. Our findings support the hy-
pothesis that patch delivery in pigs does not cause the innate activation
necessary for immunogenicity; this is in contrast to EP or even simple
ID. Therefore, inclusion of an inflammatory adjuvant could be bene-
ficial to patch immunogenicity, such as shown in pigs in the case of the
skin administration of protein hepatitis B surface antigen (HBsAg)
coated onto polyanhydride poly(bis(p-carboxy-phenoxy)propane mi-
croneedle [49] or in dissolvable microneedle patches with QS-21 [68].
In the latter case, HBsAg-specific antibody responses were not induced
in the absence of adjuvant. Alternatively, non-ablative fractional laser
treatment [69] may also enhance DNA patch immunogenicity. Spring-
loaded applicators have been tested in human with coated microneedle
arrays and it has been suggested that these induced a necrotic-based
inflammatory reaction which adjuvants the immune response to an-
tigen [70]. TLR4 and 9 ligands were previously shown in mice to sy-
nergize with DNA vaccination [12]. A TLR7 ligand, which induces a
strong skin inflammation [71], may be particularly suitable in the case
of DNA-loaded patches. Further work is required to identify an adjuvant
that induces strong vaccine-induced immunity while minimizing skin
reactions and to understand which innate cell populations are required
for this response.
pPRRSV-AG DNA combined to cationic PLGA NPs and loaded on
patches did not induce significant IFNγ T-cell responses nor IgG re-
sponses. It should be emphasized that PRRSV-AG are intrinsically weak
antigens [72], and this property may have affected the immunogenicity
results that we obtained in our side-by-side assessment of DNA delivery
methods. Indeed, as a matter of comparison with other DNA vaccines
delivered by simple ID in pigs, antibody responses against pseudorabies
[73,74] or foot and mouth disease viruses [75] [76] were detected after
one or two DNA vaccine injections, which is not the case with our
PRRSV DNA vaccine, for which 3 injections were needed to detect anti-
N IgG with the very sensitive commercial ELISA. Notably, despite the
low intrinsic immunogenicity of PRRSV-AGs, we found that EP delivery
induced substantial IgG responses and IFNγ T-cell responses, especially
when the DNA was combined to cationic PLGA NP, a regimen which
increased the breadth of the T-cell response. We did not observe an
effect of cationic PLGA NPs on skin cell transduction nor cytokine
production at 24 h, but some effect on myeloid cell recruitment, notably
of the MHC class IIpos CD163int and CD163neg cells. The positive effect
of cationic PLGA NPs versus plain EP on the IFNγ T-cell response may
be related to this myeloid cell recruitment, to an improved DNA sensing
during DNA uptake, or to changes in the transduced cell type. Notably,
the magnitude of the B and T-cell responses that was achieved with
EP+NP are in the same order as the one reported after immunization
with attenuated PRRSV vaccines in previous reports [47,77,78].
Therefore our EP+NP regimen is a promising delivery strategy,
especially in the perspective of a vaccine development relying on broad
T-cell responses. It may also be advantageously used as a priming
vaccine with an attenuated PRRSV vaccine boost, in order to optimize
the T-cell response breadth and develop effective control strategies of
this damaging infection in the pig industry.
The framework of our study in pig, that includes antigen expression
and innate and adaptive immunity assessments, could be adapted to the
other type of nucleic acid-based vaccine, the RNA vaccine, which holds
high promises in vaccinology. The fragility of RNA has been the major
hurdle against the wide development of RNA vaccines but recent
methods have considerably improved RNA stabilization and reduced
adverse reactive responses [1,2]. RNA vaccines share many properties
with DNA vaccines but they have potential advantages over DNA vac-
cines regarding safety (no risk of integration in the genome), easier
production (no high scale fermentation), and immunogenicity [79,80].
For the moment, the higher number of conducted clinical trials with
DNA versus RNA vaccines [3] and the authorization for use in veter-
inary medicine [9,10] together with the current higher stability outside
cold chain, continue to give support to the DNA vaccines, but RNA
vaccines may reveal to be more immunogenic and possibly cost-effec-
tive in the long run [79,80]. As RNA and DNA vaccines differ in the
number of membranes to be crossed for expression, and in the sensing
pathways for triggering innate immunity [2], optimal delivery methods
may differ. As RNA vaccines appear to be well delivered with liposome-
based technology [79,80] and are intrinsically highly immuno-stimu-
latory [81], their delivery with patches may lead to better im-
munogenicity results than that of DNA, and should be evaluated in the
near future.
5. Conclusion
Altogether, our study shows that surface electroporation with ca-
tionic NP is the most efficient DNA delivery method to elicit T and B cell
responses in pigs. New portable systems using the EP principle suggest
that this technology has a practical clinical future both in human and
possibly in veterinary medicine [59]. Although dissolvable microneedle
patches were efficient at delivering DNA vaccines and resulted in good
transgene expression in skin, patch-based delivery did not induce in-
flammatory signaling and detectable immunogenicity and could be
improved with adjuvants for eliciting the desired adaptive immune
response in the pig and likely in human.
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